SS-31

Accelerating

SS-31 appears in 258 indexed publications going back to 1993, including 46 in the past twelve months. 29 registered trials appear on ClinicalTrials.gov, 1 with Australian sites.

258

Indexed publications

Past 12 months, against 28 the year before

Registered clinical trials

1,644

Monthly readers on Wikipedia, down 28%

On This Figure
Published mostly under the name elamipretide. A mitochondrial context filter removes unrelated SS-31 sample codes.

Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
2015	7
2016	10
2017	13
2018	16
2019	20
2020	21
2021	23
2022	18
2023	19
2024	20
2025	32
2026	35

Public Attention

Who is looking it up

Monthly readers of the SS-31 article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

2025-082026-07

Clinical Trials

The registered pipeline

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

1 trial has a registered Australian site.

Phase distribution across the most recently updated registered trials.

Recruiting·Phase 4
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Stealth BioTherapeutics Inc. · estimated completion 2029-09-30
Active, not recruiting·Phase 3
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics Inc. · estimated completion 2027-08
Recruiting·Phase 2
Study of Healthy Aging and Physical Function With Elamipretide
David Marcinek · completed 2026-03-15
AVAILABLE
An Intermediate Size Expanded Access Protocol of Elamipretide
Stealth BioTherapeutics Inc.
Completed·Phase 2
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Stealth BioTherapeutics Inc. · completed 2022-02-22
Completed·Phase 2
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
Stealth BioTherapeutics Inc. · completed 2018-10-05

References

Most recent work

The newest indexed records mentioning SS-31, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

2026-07-10·Bioactive materials
Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis
Li T, Zheng A, Zhu C et al.
2026-07-01·Journal of radiation research
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence
Xie L, Wu J, Fan J et al.
2026-07-07·Orphanet journal of rare diseases
Elamipretide in pediatric Barth syndrome: from heart failure to school return
Amedro P, Andrianoely M, Gohier P et al.
2026-06-25·Nano letters
Topology-Controlled PEGylation Enhances Renal Accumulation of Therapeutic Peptide for Treating Ischemia-Reperfusion Injury
Wen Y, Zhao Z, Zheng X et al.
2026-05-02·Neurochemistry international
Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury
Song Z, Ban Z, Zhao H et al.
2026-06-15·Circulation. Heart failure
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model
Vahle B, Weidner S, Tomalka A et al.
2026-06-01·Chemical biology & drug design
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function
Stefaniak E, Cui B, Yan X et al.
2026-04-16·Redox biology
Peroxiredoxin Ⅲ safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H<sub>2</sub>O<sub>2</sub> detoxification
Park JW, Jang SY, Kim MY et al.

In the Catalogue

SS-31 available from Polaris Research

SS-31 10mg

Energy & Longevity

$0.89View product

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-08-02.